Education
About Us
Working with TipRanks
Follow Us
Polynovo Limited (AU:PNV)
ASX:PNV
PNV Stock Chart & Stats
AU$1.21
AU$0.01(0.49%)
At close: 4:00 PM EST
AU$1.21
AU$0.01(0.49%)
Day’s Range― - ―
52-Week RangeAU$0.90 - AU$2.07
Previous CloseN/A
Volume733.50K
Average Volume (3M)1.48M
Market Cap
AU$673.57M
Enterprise ValueAU$619.18M
Total Cash (Recent Filing)AU$29.26M
Total Debt (Recent Filing)AU$31.74M
Price to Earnings (P/E)52.6
Beta2.10
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding690,843,000
10 Day Avg. Volume1,478,953
30 Day Avg. Volume1,476,427
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)9.95
Price to Sales (P/S)6.51
P/FCF Ratio-76.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.85Price Target Upside52.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Growth & U.S. Account ExpansionSustained double‑digit group and U.S. revenue growth and steady new hospital account additions show durable commercial adoption. A broadened account base and >80 U.S. reps reduce single‑customer risk and support recurring procedure volumes and predictable hospital procurement demand.
Very High Gross Margins & Rising ProfitabilityExceptionally high gross margins indicate strong product economics from the NovoSorb platform, enabling significant operating leverage. Improving adjusted EBITDA demonstrates scalable margin conversion as sales grow, supporting reinvestment in commercial and regulatory activities without eroding unit economics.
Manufacturing Scale‑up And Regulatory ProgressA validated facility with ~5x capacity materially improves supply scalability and lowers unit risk for multi‑SKU growth. Concurrent PMA progress with BARDA builds a regulatory moat for key indications, enabling expanded hospital adoption and stable revenue channels across institutional markets.
Bears Say
Weak Cash Conversion & FCF DynamicsDespite revenue and margin strength, weak free cash flow conversion and low OCF-to-net‑income create funding sensitivity. Persistent negative FCF growth can constrain reinvestment, extend payback on commercial expansion, and increase reliance on equity or debt during scale‑up phases.
Outpatient Reimbursement And Regulatory UncertaintyOutpatient channels represent meaningful incremental market opportunity, but exigent CMS coverage requiring RCT evidence delays monetization. Uncertain timing and trial requirements mean outpatient revenue is not guaranteed, slowing diversification away from hospital and burn‑centric volumes.
Lumpy Demand And Limited Near‑term VisibilityA business exposed to episodic burn volumes and seasonal case variability complicates forecasting and capacity planning. Combined with no formal guidance, this raises execution risk for scaling manufacturing and commercial spend, making outcome timing and cash flow less predictable.
Polynovo News
PNV FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest share price was AU$0.90 and its highest was AU$2.07 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is AU$673.57M.
When is Polynovo Limited’s upcoming earnings report date?
Polynovo Limited’s upcoming earnings report date is Aug 21, 2026 which is in 181 days.
How were Polynovo Limited’s earnings last quarter?
Polynovo Limited released its earnings results on Feb 20, 2026. The company reported AU$0 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.006.
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Polynovo Limited reported an EPS of AU$0 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -8.458%.
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in AU:PNV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$1.85 (52.89% Upside)
AU$1.85 (52.89% Upside)
Blogger Sentiment
Bullish
AU:PNV Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $263.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.28%
12-Months-Change
Fundamentals
Return on Equity
16.49%
Trailing 12-Months
Asset Growth
15.63%
Trailing 12-Months
Company Description
Polynovo Limited
Polynovo (PNV) is a medical technology company focused on developing and commercializing innovative products for the healthcare sector, particularly in the fields of wound care and regenerative medicine. The company specializes in biodegradable polymers and its core products include the NovoSorb polymer technology, which is utilized in various applications such as dermal scaffolds, wound dressings, and advanced tissue regeneration solutions. Polynovo aims to improve patient outcomes through its cutting-edge biomedical products while addressing unmet medical needs in the market.
PNV Company Deck
PNV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and commercial picture: double‑digit revenue growth across major regions (group +26%, U.S. +25.3%, RoW +28.3%), rapid MTX adoption (~+193%), improved cash flow (+$9.0M) and a strong clinical evidence base (348 studies). Key strategic catalysts (PMA submission, SynPath outpatient pathway, expanded manufacturing capacity, recruitment of a Chief Scientific Officer) provide clear upside. Short‑term headwinds include a timing‑related manufacturing variance (~$3.6–3.7M) from planned slowdowns, an R&D lab fire asset write‑off (insured), FX translation losses, and reimbursement/regulatory uncertainty for outpatient CMS coverage which may require an RCT. Management frames several negatives as one‑offs or timing issues and expects margin and free cash flow improvement in H2. Overall, highlights materially outweigh the lowlights.View all AU:PNV earnings summariesPNV Stock 12 Month Forecast
Average Price Target
AU$1.85
▲(52.89% Upside)
Technical Analysis
Somnomed Limited
―
Cyclopharm Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---